AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19484680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 17698939 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding intermediate measures
Number of subjects: 0
Study 17698939 — intervention group
Group type: EXPERIMENTAL
Intervention: Design with three repeated measures
Number of subjects: 0
Study 17698939 — intervention group
Group type: EXPERIMENTAL
Intervention: Design with more than three measures
Number of subjects: 0
Study 17698939 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal design based on first-order auto-regressive structure with measurement error
Number of subjects: 0
Study 15123939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated prostheses
Number of subjects: 24
Study 15123939 — intervention group
Group type: COMPARATOR
Intervention: Noncoated prostheses
Number of subjects: 24
Study 11549097 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg (oral capsule or intravenous infusion)
Number of subjects: 10
Study 9626609 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 cash incentive plus standardized TB education
Number of subjects: 79
Study 9626609 — intervention group
Group type: COMPARATOR
Intervention: Standardized TB education alone
Number of subjects: 79
Study 8142265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (FT + TAM 20 mg day‐1 for 2 years after DOX administration)
Number of subjects: 512
Study 8142265 — intervention group
Group type: COMPARATOR
Intervention: Treatment A (FT 50 mg day‐1 for 2 years after DOX administration)
Number of subjects: 512
Study 8142265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (FT + TAM 20 mg day‐1 for 2 years)
Number of subjects: 512
Study 2802643 — intervention group
Group type: EXPERIMENTAL
Intervention: bendroflumethiazide (bendrofluazide)
Number of subjects: 22
Study 2802643 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Number of subjects: 22
Study 2802643 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 769751 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental rooms (not cleaned between consecutive clean operations, cleaned after contaminated operations)
Number of subjects: 2020
Study 769751 — intervention group
Group type: COMPARATOR
Intervention: Control rooms (uniformly received Wet‐Vac cleaning between operations)
Number of subjects: 2020
Study 30707049 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime (qhs)
Number of subjects: 2465
Study 30707049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2465
Study 29211803 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic bed rest (NBR)
Number of subjects: 231
Study 29211803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic bed rest (HBR)
Number of subjects: 231
Study 29211803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic ambulation (HAmb)
Number of subjects: 231
Study 29211803 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivity combined with hypoxia
Number of subjects: 231
Study 26356615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml per day for 10 days)
Number of subjects: 373
Study 26356615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml per day from 11th to 20th day)
Number of subjects: 373
Study 26356615 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (control group)
Number of subjects: 373
Study 26356615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20-day therapy)
Number of subjects: 373
Study 26356615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (10-day therapy)
Number of subjects: 373
Study 23496988 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved oral health care and a diet of increased consistency
Number of subjects: 0
Study 23496988 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study 22127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sequential estrogen plus progestin (n = 52)
Number of subjects: 106
Study 22127965 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 106
Study 19851520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin (3200, 4250, 6400, or 12800 IUaXa) administered subcutaneously once daily for 3 to 5 days to 6 months
Number of subjects: 0
Study 19851520 — intervention group
Group type: COMPARATOR
Intervention: Parnaparin
Number of subjects: 0
Study 17384437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg once per day (n = 2072)
Number of subjects: 4133
Study 17384437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2061)
Number of subjects: 4133
Study 17384437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg once per day
Number of subjects: 4133
Study 17384437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 15282005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 30
Study 15282005 — intervention group
Group type: COMPARATOR
Intervention: Abdominal Hysterectomy (AH)
Number of subjects: 30
Study 10972580 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose infusion
Number of subjects: 8
Study 10972580 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 8
Study 8630518 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH 0.1 IU/kg body wt per day)
Number of subjects: 40
Study 8630518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1569442 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (one cycle)
Number of subjects: 1275
Study 1569442 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 1275
Study 6372372 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 241
Study 6372372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 31104758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative rScO2 monitoring
Number of subjects: 153
Study 29946346 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed wound closure
Number of subjects: 607
Study 29946346 — intervention group
Group type: COMPARATOR
Intervention: Primary wound closure
Number of subjects: 607
Study 29946346 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction score
Number of subjects: 607
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (flying needling therapy + clomiphene)
Number of subjects: 90
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Flying needling therapy group
Number of subjects: 90
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group (clomiphene)
Number of subjects: 90
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 90
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 90
Study 29231300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group and Flying needling therapy group
Number of subjects: 90
Study 24993832 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 100
Study 24993832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 100
Study 24993832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22012708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0
Study 22012708 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 19460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT
Number of subjects: 75
Study 19460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Eagle Bond
Number of subjects: 75
Study 19460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Bond
Number of subjects: 75
Study 19460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blugloo
Number of subjects: 75
Study 19460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Unite
Number of subjects: 75
Study 17308275 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 174
Study 17308275 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 174
Study 14690654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) with a 7.5 MHz curved array transducer
Number of subjects: 60
Study 14690654 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 60
Study 12214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for achalasia
Number of subjects: 0
Study 12214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for sphincter of Oddi dysfunction (SOD)
Number of subjects: 0
Study 12214336 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox) for chronic anal fissure
Number of subjects: 0
Study 9696171 — intervention group
Group type: COMPARATOR
Intervention: Droperidol
Number of subjects: 202
Study 9696171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 202
Study 9696171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 202
Study 8133491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Number of subjects: 0
Study 8133491 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 0.1%
Number of subjects: 0
Study 2506598 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg PO lorazepam
Number of subjects: 20
Study 1160798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydergot
Number of subjects: 148
Study 1160798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 30859545 — intervention group
Group type: EXPERIMENTAL
Intervention: Power plant emission reduction technologies
Number of subjects: 0
Study 30859545 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28570966 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐focused therapy for adolescents (FFT‐A) plus pharmacotherapy
Number of subjects: 141
Study 28570966 — intervention group
Group type: COMPARATOR
Intervention: Brief psychoeducation (enhanced care, or EC) plus pharmacotherapy
Number of subjects: 141
Study 25644344 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (27 g/supplement, twice daily)
Number of subjects: 40
Study 25644344 — intervention group
Group type: COMPARATOR
Intervention: Soy protein supplementation (26 g/supplement, twice daily)
Number of subjects: 40
Study 25644344 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplementation (25 g maltodextrin/supplement, twice daily)
Number of subjects: 40
Study 23562339 — intervention group
Group type: EXPERIMENTAL
Intervention: Early EVAR
Number of subjects: 728
Study 23562339 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 728
Study 22074419 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE variant alleles (C282Y, H63D)
Number of subjects: 332
Study 22074419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hfe(‐/‐) mice
Number of subjects: 332
Study 22074419 — intervention group
Group type: COMPARATOR
Intervention: No significant intervention
Number of subjects: 332
Study 19257898 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-AS (sulphadoxine-pyrimethamine combined with artesunate)
Number of subjects: 0
Study 19257898 — intervention group
Group type: COMPARATOR
Intervention: SP (sulphadoxine-pyrimethamine)
Number of subjects: 0
Study 19257898 — intervention group
Group type: COMPARATOR
Intervention: CQ (chloroquine)
Number of subjects: 0
Study 16457914 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with patellar resurfacing
Number of subjects: 34
Study 16457914 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty without patellar resurfacing
Number of subjects: 34
Study 15193677 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (24 microg/kg)
Number of subjects: 24
Study 15193677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10828727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 mg
Number of subjects: 24
Study 10828727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10828727 — intervention group
Group type: COMPARATOR
Intervention: RLS patients
Number of subjects: 24
Study 10828727 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study 9344297 — intervention group
Group type: EXPERIMENTAL
Intervention: FNS ambulation training sessions using the Parastep 1 system (32 sessions)
Number of subjects: 15
Study 8251279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg (Navoban)
Number of subjects: 69
Study 8251279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 3546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 1 of phenytoin
Number of subjects: 60
Study 3546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 2 of phenytoin
Number of subjects: 60
Study 3546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 3 of phenytoin
Number of subjects: 60
Study 3546122 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand 4 of phenytoin
Number of subjects: 60
Study 31447402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent motion intervention system
Number of subjects: 0
Study 31447402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 29864432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 60 mg over 3 perioperative days
Number of subjects: 93
Study 29864432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 93
Study 26861147 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal ultrasound-guided popliteal block
Number of subjects: 60
Study 26861147 — intervention group
Group type: COMPARATOR
Intervention: Proximal ultrasound-guided popliteal block
Number of subjects: 60
Study 25899914 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized loading dose (LD) regimen of cholecalciferol, 50,000 IU twice a week, followed by a monthly maintenance dose of either 50,000 or 25,000 IU
Number of subjects: 30
Study 25899914 — intervention group
Group type: COMPARATOR
Intervention: Daily dose (DD) regimen of cholecalciferol, 800 IU daily for 26 weeks
Number of subjects: 30
Study 23094678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued trials (AE group)
Number of subjects: 35
Study 23094678 — intervention group
Group type: EXPERIMENTAL
Intervention: No-go trials (AE group)
Number of subjects: 35
Study 23094678 — intervention group
Group type: COMPARATOR
Intervention: Cued trials (CON group)
Number of subjects: 35
Study 21134278 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational strategy (nutritional lessons, working groups, final party)
Number of subjects: 5458
Study 21134278 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening strategy (detecting overweight/obesity and eating disorders, 7 group educational sessions)
Number of subjects: 5458
Study 21134278 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental strategy (improving dietary and physical activity offerings in high schools)
Number of subjects: 5458
Study 18216672 — intervention group
Group type: EXPERIMENTAL
Intervention: Procrit and Cell Saver
Number of subjects: 79
Study 18216672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79
Study 17722306 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol LCT with lidocaine pretreatment
Number of subjects: 360
Study 17722306 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT with lidocaine pretreatment
Number of subjects: 360
Study 17722306 — intervention group
Group type: COMPARATOR
Intervention: Propofol MCT/LCT without lidocaine pretreatment
Number of subjects: 360
Study 17722306 — intervention group
Group type: COMPARATOR
Intervention: Propofol LCT with saline pretreatment
Number of subjects: 360
Study 14624170 — intervention group
Group type: EXPERIMENTAL
Intervention: Terumo ES-H55 double-cuff sphygmomanometer
Number of subjects: 87
Study 14624170 — intervention group
Group type: COMPARATOR
Intervention: Auscultatory method
Number of subjects: 87
Study 10072024 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA with fiberoptic guidance (ILMA‐FOB)
Number of subjects: 90
Study 10072024 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA inserted blindly (ILMA‐Blind)
Number of subjects: 90
Study 10072024 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (laryngoscopy group)
Number of subjects: 90
Study 8575576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 10-80 micrograms
Number of subjects: 35
Study 8575576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 20, 40, and 80 micrograms
Number of subjects: 35
Study 8575576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8575576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide doses
Number of subjects: 35
Study 8575576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 35
Study 1827799 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (50 mg/day) plus UVB therapy
Number of subjects: 0
Study 1827799 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus UVB therapy
Number of subjects: 0
Study 1827799 — intervention group
Group type: COMPARATOR
Intervention: Acitretin alone
Number of subjects: 0
Study 7315712 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 190
Study 7315712 — intervention group
Group type: COMPARATOR
Intervention: Urgent coronary artery bypass surgery (CABG)
Number of subjects: 190
Study 31587979 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression and PRP‐incorporated autologous granular bone grafting (treatment group)
Number of subjects: 46
Study 31587979 — intervention group
Group type: COMPARATOR
Intervention: Core decompression and autologous granular bone grafting (control group)
Number of subjects: 46
Study 31587979 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 46
Study 31587979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 31199778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-based Severity of Dependence Scale (SDS)
Number of subjects: 97
Study 31199778 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported written version of Severity of Dependence Scale (SDS)
Number of subjects: 97
Study 31199778 — intervention group
Group type: COMPARATOR
Intervention: Comparison of interview-based SDS vs self-reported SDS
Number of subjects: 97
Study 28324697 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Number of subjects: 70
Study 28324697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 26234800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education and support (DSME/S) intervention
Number of subjects: 108
Study 26234800 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 23053062 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg desloratadine
Number of subjects: 29
Study 23053062 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg desloratadine
Number of subjects: 29
Study 23053062 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 29
Study 20015100 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen incandescent bulbs
Number of subjects: 70
Study 20015100 — intervention group
Group type: COMPARATOR
Intervention: Low-energy fluorescent tubes
Number of subjects: 70
Study 20015100 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for light source
Number of subjects: 70
Study 20015100 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity comparison
Number of subjects: 70
Study 19564277 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (90 mg/kg) with potassium clavulanate (6.4 mg/kg)
Number of subjects: 58
Study 19564277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 16303845 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg p.o. qid for 2 weeks)
Number of subjects: 10
Study 16303845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15518626 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 50 mg
Number of subjects: 96
Study 15518626 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 (other doses)
Number of subjects: 96
Study 15518626 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 96
Study 15518626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 12366646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 28
Study 12366646 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study 9824802 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized guideline intervention for vancomycin use
Number of subjects: 1798
Study 9824802 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 1798
Study 8552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisson-based design for recurrent events
Number of subjects: 0
Study 8552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric tests proposed by Lawless and Nadeau
Number of subjects: 0
Study 8552888 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric tests
Number of subjects: 0
Study 2496577 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 15 mg daily
Number of subjects: 22
Study 2496577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21973 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-valent pneumococcal vaccine
Number of subjects: 523
Study 21973 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-valent pneumococcal vaccine
Number of subjects: 523